Положително решение за включване на лекарствен продукт, принадлежащ към ново международно непатентно наименование (INN)

ADEMPAS, INN Riociguat

BEOVU (brolucizumab), INN Brolucizumab

Braftovi, INN Binimetinib (Mеланом в комбинация с Mektovi)

Calquence, INN Acalabrutinib

Dupixent, INN dupilumab

Evrysdi, INN Risdiplam

Fluenz Tetra, INN Influenza, live attenuated

Kalydeco, INN Ivacaftor + Kaftrio, INN Ivacaftor/Tezacaftor/Elexacaftor

Litak, INN cladribine

Lokelma, INN Sodium zirconium cyclosilicate

LORVIQUA, INN Lorlatinib

MAYZENT, INN Siponimod

Nubeqa, INN Darolutamide

Orkambi, INN Lumacaftor, ivacaftor

Phesgo, INN Pertuzumab/Trastuzumab

POLIVY, INN Polatuzumab vedotin

Rozlytrek, INN Entrectinib

RYZODEG, INN Insulin degludec/insulin aspart

Strensiq, INN Asfotase alfa

TEGSEDI, INN Inotersen

Uptravi, INN Selexipag

VICTOZA, INN Liraglutide

ZINFORO cSSTI, INN Ceftaroline fosamil

ZINFORO CAP, INN Ceftaroline fosamil